Targeting glutamine metabolism in brain tumors

Patent metadata

Field	Value
Publication number	US-2016008380-A1
Application number	US-201414772837-A
Country	US
Kind code	A1
Filing date	Mar 6, 2014
Priority date	Mar 6, 2013
Publication date	Jan 14, 2016
Grant date	—

Abstract

The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for diagnosing and treating MYC-driven tumors. In one embodiment, a method for treating a cancer associated with MYC in a patient comprises the step of administering a glutamine metabolism inhibitor to the patient. In specific embodiments, the cancer associated with MYC is medulloblastoma, glioblastoma or a primitive neuroectodermal tumor.

First claim

1 . A method for treating a cancer associated with MYC in a patient comprising the step of administering a glutamine metabolism inhibitor to the patient.

2 . The method of claim 1 , wherein the glutamine metabolism inhibitor is (2S)-Amino[(5S)-3-chloro-4,5-dihydro-1,2-oxazol-5-yl]ethanoic acid (Acivicin) or 6-Diazo-5-oxo-L-norleucine (DON).

3 . The method of claim 1 , wherein the cancer associated with MYC is medulloblastoma, glioblastoma or a primitive neuroectodermal tumor.

4 . A method for treating a cancer associated with MYC in a patient comprising the steps of:
a. obtaining a biological sample from the patient; b. assaying the biological sample to determine whether the cancer is associated with MYC; and c. administering a glutamine metabolism inhibitor to the patient if the cancer is determined to be associated with MYC.

5 . The method of claim 4 , wherein the assaying step comprises measuring the expression levels of one or more of MYC, glutaminase, glutamate dehydrogenase, ASCT2 and miR-23 and comparing the levels to a reference.

6 . The method of claim 4 , wherein the cancer associated with MYC is medulloblastoma, glioblastoma or a primitive neuroectodermal tumor.

7 . A method for identifying a cancer patient as likely to benefit from glutamine metabolic inhibitors treatment comprising the steps of:
a. obtaining biological sample from the patient; b. assaying the biological sample to determine whether the cancer is associated with MYC; and c. identifying the cancer patient as likely to benefit from glutamine metabolic inhibitor treatment if the cancer is determined to be associated with MYC.

8 . The method of claim 7 , wherein the assaying step comprises measuring the expression levels of one or more of MYC, glutaminase, glutamate dehydrogenase, ASCT2 and miR-23 and comparing the levels to a reference.

9 . The method of claim 7 , wherein the cancer associated with MYC is medulloblastoma, glioblastoma or a primitive neuroectodermal tumor.

Assignees

• Univ Johns Hopkins

Inventors

• Raabe Eric H
• Hanaford Allison
• Ahsan Sama
• Taylor Isabella
• Eberhart Charles

Classifications

• G01N2333/4703

  Regulators; Modulating activity · CPC title

• A61K31/42

  Oxazoles · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• G01N2333/98

  acting on amide bonds in linear amides (3.5.1) · CPC title

• A61K31/655 Primary

  Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds · CPC title